Zhongyang Lu

Dr. Zhongyang Lu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ZLZhongyang Lu
Zhongyang Lu
SLShufeng Liu
Shufeng Liu
MFMaria Gabriela Morales France
Maria Gabriela Morales France
AWAndy Whitlock
Andy Whitlock
RRRam Ramkumar
Ram Ramkumar
HRHema Ramkumar
Hema Ramkumar
Dry age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 with limited therapeutic options. The sodium iodate (NaIO3)-induced retinal degeneration model mimics oxidative stress-induced cell death in dry AMD. BMI1, a polycomb ring finger protein involved in DNA repair and cell renewal, is a potential therapeutic target for oxidative retinal injury. We evaluated the efficacy of AAV-mediated BMI1 gene delivery in Balb/c and C57BL/6 mice using two routes: subretinal (SR) and suprachoroidal (SC). AAV5.BMI1 (1×10⁹ vg/eye) was delivered SR in Balb/c mice, and efficacy was assessed after 4 and 15 weeks. AAV8.BMI1 (5×10⁹ or 1×10¹⁰ vg/eye) was administered SC in C57BL/6 mice, with evaluation after 4 weeks. Control groups received BSS or AAV8.stuffer. Following NaIO₃ administration, retinal function and structure were analyzed by optical coherence tomography (OCT), electroretinography (ERG), histology, and tissue assays. SC delivery of AAV8.BMI1 achieved the highest transduction and BMI1 expression without adverse effects, leading to dose-dependent ONL preservation and improved ERG responses. These findings suggest that SC AAV-mediated BMI1 gene delivery effectively enhances retinal health and function and prevents retinal degeneration, supporting its use as a promising therapeutic approach for intermediate AMD to prevent advanced disease.